News Focus
News Focus
icon url

rosemountbomber

01/18/23 4:10 PM

#398681 RE: Whalatane #398680

I think the risks re reimbursement in the EU were always underplayed .



Yep, by the company and this board. I remember how furious the board generally was with Wall Street for not "properly" valuing the EU opportunity. The company still pushes 1 billion plus for the EU and yet can't report a single dollar from there.
icon url

Laurent Maldague

01/18/23 5:00 PM

#398684 RE: Whalatane #398680

Ezetimibe RRR was only 6% I believe. Absolutely ludicrous comparator the Germans chose.